CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?

Pierpaolo Correale1, Francesca Pentimalli2, Valerio Nardone3

  • 1Medical Oncology Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.

The Lancet. Oncology
|January 1, 2022
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos